Trial Profile
Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ASCENT
- 31 Jan 2021 Status changed from recruiting to discontinued as per results presented at the 2020 World Conference on Lung Cancer.
- 31 Jan 2021 Results of final analysis presented at the 2020 World Conference on Lung Cancer.
- 01 Jul 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.